tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Zegbeh Jallah, 167 are a BUY (96.53%), 5 are a HOLD (2.89%), 1 are a SELL (0.58%).
Analyst Zegbeh Jallah, currently employed at CAPITAL ONE, carries an average stock price target met ratio of 40.07% that have a potential upside of 40.79% achieved within 340 days. Previously, Zegbeh Jallah worked at ROTH MKM.
Zegbeh Jallah’s has documented 324 price targets and ratings displayed on 27 stocks. The coverage is on Healthcare, Technology sectors.
Most recent stock forecast was given on EYPT, Eyepoint Pharmaceuticals at 25-Oct-2024.
Analyst best performing recommendations are on OCGN (OCUGEN).
The best stock recommendation documented was for OCGN (OCUGEN) at 2/3/2021. The price target of $8 was fulfilled within 5 days with a profit of $5.19 (184.7%) receiving and performance score of 369.4.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 11-Feb-2015
4 years 1 days ago
(25-Oct-2022)
0/10 (0%)
$13.99 (348.88%)
Hold Since 25-Oct-2022
$0.4
$0.01 (2.56%)
4 years 1 days ago
(25-Oct-2022)
1/1 (100%)
$0.01 (2.56%)
2
Buy Since 09-Feb-2017
$9
4 years 2 days ago
(24-Oct-2022)
1/3 (33.33%)
$7.17 (391.80%)
104
Hold Since 24-Oct-2022
$0.34
$-0.05 (-12.82%)
4 years 2 days ago
(24-Oct-2022)
0/5 (0%)
$-0.05 (-12.82%)
Buy Since 11-Nov-2020
4 years 27 days ago
(29-Sep-2022)
0/2 (0%)
$6.72 (157.01%)
What Year was the first public recommendation made by Zegbeh Jallah?
